Equities analysts predict that ABIOMED, Inc. (NASDAQ:ABMD) will report earnings of $0.73 per share for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for ABIOMED’s earnings. The lowest EPS estimate is $0.68 and the highest is $0.78. ABIOMED posted earnings per share of $0.44 during the same quarter last year, which indicates a positive year over year growth rate of 65.9%. The firm is scheduled to announce its next earnings results before the market opens on Thursday, November 1st.
On average, analysts expect that ABIOMED will report full-year earnings of $4.63 per share for the current fiscal year, with EPS estimates ranging from $4.43 to $4.88. For the next fiscal year, analysts anticipate that the firm will report earnings of $4.73 per share, with EPS estimates ranging from $4.50 to $5.36. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover ABIOMED.
ABIOMED (NASDAQ:ABMD) last issued its quarterly earnings results on Thursday, July 26th. The medical equipment provider reported $1.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.80 by $1.15. ABIOMED had a net margin of 25.71% and a return on equity of 18.91%. The business had revenue of $180.01 million for the quarter, compared to analyst estimates of $173.87 million. During the same period in the previous year, the business posted $0.82 earnings per share. The business’s revenue was up 35.9% compared to the same quarter last year.
ABMD has been the topic of a number of recent analyst reports. BidaskClub lowered shares of ABIOMED from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, June 26th. Zacks Investment Research upgraded shares of ABIOMED from a “hold” rating to a “buy” rating and set a $457.00 price target on the stock in a research note on Tuesday, July 10th. ValuEngine lowered shares of ABIOMED from a “strong-buy” rating to a “buy” rating in a research note on Saturday, August 18th. Morgan Stanley boosted their price target on shares of ABIOMED from $370.00 to $396.00 and gave the stock an “equal weight” rating in a research note on Thursday, October 11th. Finally, Piper Jaffray Companies boosted their price target on shares of ABIOMED from $360.00 to $480.00 and gave the stock an “overweight” rating in a research note on Friday, June 22nd. Three investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $384.38.
In related news, COO David M. Weber sold 19,282 shares of the business’s stock in a transaction dated Monday, July 30th. The shares were sold at an average price of $356.77, for a total transaction of $6,879,239.14. Following the sale, the chief operating officer now owns 167,124 shares of the company’s stock, valued at $59,624,829.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Michael G. Howley sold 10,000 shares of the business’s stock in a transaction dated Tuesday, September 25th. The stock was sold at an average price of $432.50, for a total transaction of $4,325,000.00. Following the sale, the vice president now directly owns 48,954 shares in the company, valued at approximately $21,172,605. The disclosure for this sale can be found here. In the last three months, insiders have sold 33,722 shares of company stock worth $12,958,039. 3.50% of the stock is owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in the stock. TRUE Private Wealth Advisors purchased a new stake in shares of ABIOMED in the third quarter valued at about $162,000. Oakbrook Investments LLC lifted its holdings in shares of ABIOMED by 47.5% in the third quarter. Oakbrook Investments LLC now owns 4,120 shares of the medical equipment provider’s stock valued at $1,853,000 after purchasing an additional 1,326 shares in the last quarter. Aperio Group LLC lifted its holdings in shares of ABIOMED by 14.0% in the third quarter. Aperio Group LLC now owns 24,583 shares of the medical equipment provider’s stock valued at $11,056,000 after purchasing an additional 3,016 shares in the last quarter. MERIAN GLOBAL INVESTORS UK Ltd lifted its holdings in shares of ABIOMED by 1,030.0% in the third quarter. MERIAN GLOBAL INVESTORS UK Ltd now owns 638,856 shares of the medical equipment provider’s stock valued at $287,325,000 after purchasing an additional 582,318 shares in the last quarter. Finally, Nisa Investment Advisors LLC lifted its holdings in shares of ABIOMED by 13.5% in the third quarter. Nisa Investment Advisors LLC now owns 62,851 shares of the medical equipment provider’s stock valued at $24,631,000 after purchasing an additional 7,460 shares in the last quarter. 86.21% of the stock is currently owned by hedge funds and other institutional investors.
Shares of ABIOMED stock traded down $3.16 on Thursday, reaching $386.63. 462,800 shares of the stock were exchanged, compared to its average volume of 632,518. ABIOMED has a 1-year low of $164.80 and a 1-year high of $459.75. The firm has a market cap of $20.18 billion, a price-to-earnings ratio of 157.81, a price-to-earnings-growth ratio of 4.81 and a beta of 0.03.
ABIOMED, Inc engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite.
Further Reading: Average Daily Trade Volume – What It Means In Stock Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.